natgillin/translations-raw huggingface dataset:
The integrated circuit according to claim 1, wherein the first aggregation level value is 1 or 2 and the second aggregation level value is 4 or 8. 
Naprava za prijem sukaldno jednom od zahtjeva od 5 do 7, naznačena time da je prva vrijednost razine agregacije 2 i da je druga vrijednost razine agregacije 4 ili 8.
The antibody or an antigen-binding portion thereof according to claim 4 wherein said drug is selected from the group consisting of a maytansinoid, a dolastatin, an auristatin, a trichothecene, a calicheamicin, CC1065 and derivatives thereof. 
Protutijelo ili njegov antigen-vezujući dio sukladno patentnom zahtjevu 4 gdje je navedeni lijek odabran iz skupine sastavljene od maitanzinoida, dolastatina, auristatina, trihotecena, kalikeamicina, CC1065 1 njihovih derivata.
The method according to any one of the preceding claims, further comprising the step of connecting at least two prefabricated modules to each other in the direction of the length of the modules. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, nadalje sadrži korak spajanja barem dva prethodno proizvedena modula u smjeru duljine modula.
is hydrogen, or C1-C6 alkyl; or a pharmaceutically acceptable salt, hydrate, solvate or complex thereof. 
R* je vodik, ili C,-Cz alkil; ili njegova farmaceutski prihvatljiva sol, hidrat, solvat ili kompleks.
1 shows a view in perspective of a beacon in accordance with the teachings of the present invention; 
prikazuje perspektivni izgled balize u skladu s tumačenjima predmetnog izuma; Slika 2
contacting the amide solvate of the compound of formula (II) with an amine under conditions suitable for forming an amine salt of the compound of formula (II); and contacting the amine salt of the compound of formula (II) with a reagent comprising sodium ions under conditions suitable for forming the compound of formula (I) or hydrate thereof. 
O=P-OH | (ll) OH s aminom pod uvjetima koji su pogodni za nastajanje soli amina spoja s formulom (II); i b) dovođenje u kontakt soli amina s reagensom koji sadrži natrijeve ione pod uvjetima koji su pogodni za nastajanje spoja s formulom (1) ili njegovog hidrata.
is imidazolyl, pyrimidinyl, triazolyl, tetrahydropyranyl, thiazolyl, pyridyl, piperidinyl, phenyl, or oxazolyl; wherein said piperidinyl, pyridyl, imidazolyl, and phenyl are optionally substituted with SO2CH3, C(O)CH3, CH3, CF3, Cl, F, -CN, OCH3, -CF3, or N(CH3)2; and optionally substituted with up to one additional group independently selected from Cl, OCH3, and CH3; and wherein said triazolyl, oxazolyl, and thiazolyl are optionally substituted with one or two CH3 groups; 
R' je imidazolil, pirimidinil, triazolil, tetrahidropiranil, tiazolil, piridil, piperidinil, fenil, ili oksazolil; pri čemu su navedeni piperidinil, piridil, imidazolil, i fenil proizvoljno supstituirani s SO;CH:, C(O)CH>, CH4, CF, CI, F, -CN, OCH, -CF3, ili N(CH3);; i proizvoljno supstituirani s do jednom dodatnom skupinom koja je neovisno odabrana iz CL, OCH, i CH3; 1 pri čemu su navedeni triazolil, oksazolil, i tiazolil proizvoljno supstituirani s do jednom ili dvije skupine CH;;
The process according to one of the claims 1 to 7, wherein the liquid phase of the suspension further comprises water. The process according to claim 9, wherein the water and the organic solvent form an emulsion. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da tekuća faza suspenzije nadalje sadrži vodu, poželjno pri čemu voda i organsko otapalo tvore emulziju.
An inserter according to claim 1 or 3, characterised in that the slider (5) and/or the insertion tube (6) comprises at least one extension adapted to abut on the abutment surface of the first extension of the main part of the locking means. 
Aplikator za umetanje prema bilo kojem od zahtjeva 3-5, naznačen time što klizač (5) 1/ili cjevčica za umetanje (6) obuhvaća barem jedan produžetak prilagođen da se naslanja na graničnu površinu prvog produžetka glavnog dijela sredstva za zaključavanje.
The method of any of paragraphs 49-50, wherein the compound or composition administered to the subject can comprise a therapeutic moiety that can comprise a targeting moiety that can act as an inhibitor against Ras, PTP1B, Pinl, Grb2 SH2, or combinations thereof. 
Lek prema patentnom zahtjevu 13, naznačen time, što je terapijski agens inhibitor koji djeluje protiv Ras, PTPIB, Pinl, Grb2, SH2, ili njihovih kombinacija.
The method of claim 1, wherein the compounds are formulated or administered together, separately or sequentially. 
Smjesa za uporabu prema bilo kojem od zahtjeva 1 do 6, gdje su spojevi oblikovani ili primijenjeni zajedno, odvojeno ili uzastopce.
removing the G groups to form a compound of formula (VIIa) or (VIIb): or an acid addition salt thereof. 
(d) uklanjanje G grupa da bi se formirao spoj formule (VIIa) ili (VIIb): R!
A pharmaceutical composition comprising a therapeutically effective amount of the (S)-PG crystal structure as defined in Embodiment 5 and a pharmaceutically acceptable carrier or diluent. E-18. 
Farmaceutski pripravak kako je definirano u zahtjevu 9 naznačen time da sadrži terapeutski učinkovitu količinu kristalne strukture mono (S)-propilen glikol mono hidrata (S)-PG 1 farmaceutski prihvatljiv nosač ili razrjeđivač.
Use of a compound represented by the formula (I) wherein R1 is as defined in claim 1, or a salt thereof, in combination with a biguanide, for manufacture of an agent for the prophylaxis or treatment of diseases in which insulin resistance is involved. 
N. CH3CH,O- N (I) gdje R! je kao definiran u zahtjevu 1, ili njegova sol, u kombinaciji s bigvanidom, za proizvodnju sredstva za profilaksu ili liječenje oboljenja u kojima je 5
Apparatus according to claim 1, wherein the filtration means comprises cartridge filters, sand filters, micro-filters, ultra-filters, nano-filters, or a combination thereof. 
Uređaj za obradu vode uz nizak trošak, prema bilo kojem prethodnom zahtjevu, naznačen time što sredstva za filtriranje (3) sadrže filterske uloške, pješčane filtre, mikro-filtre, ultra-filtre, nano-filtre, ili njihovu kombinaciju.
In order to supply the LNG of the liquid state as fuel gas, the liquefied gas treatment system according to the present embodiment includes a main LNG supply line L23 serving to supply the main engine with LNG stored in the cargo tank 11, and a sub LNG supply line L24 branched from the main LNG supply line L23 to supply the sub engine with LNG. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što crpka uključuje: crpku za pražnjenje (2; 12), ugrađenu u skladišni spremnik radi pražnjenja LNG u vanjštinu spremnika za teret; i visokotlačnu (120;43) crpku, podešenu za sekundarno komprimiranje LNG, koji se primarno komprimira u crpki za pražnjenje, do tlaka potrebnog za glavni motor.
Use of aclidinium in free or pharmaceutically acceptable salt form in the manufacture of a medicament for treating a respiratory condition selected from asthma and chronic obstructive pulmonary disease in a patient in need of such treatment, said use comprising (i) administering once daily a fine particle dose of aclidinium equivalent to 120 µg (plus/minus 35%) aclidinium bromide or (ii) administering twice daily a fine particle dose of aclidinium equivalent to 120 µg (plus/minus 35%) aclidinium bromide. 
Primjena aklidinija u slobodnom obliku ili u obliku farmaceutski prihvatljive soli u proizvodnji lijeka za liječenje kronične opstruktivne plućne bolesti u bolesnika kojem je potrebno takvo liječenje, pri čemu se spomenuta primjena sastoji od davanja inhalacijom jednom ili dvaput dnevno odmjerene nominalne doze aklidinija jednake 400 mikrograma (plus/minus 10 %) aklidinijevog bromida.
As mentioned above the size of the dose required for the therapeutic or prophlyactic treatment of a particular disease will necessarily be varied depending upon, amongst other things, the host treated, the route of administration and the severity of the illness being treated. 
Kao što je spomenuto gore veličina doze potrebne za terapeutsko ili profilaktičko liječenje određene bolesti nužno će varirati u ovisnosti o, među ostalim, domaćinu kojeg se liječi, načinu davanja lijeka i težine bolesti koju se liječi.
EMBODIMENTS A method of forming a wear resistant layer comprising transparent or semitransparent wear resistant particles (15) on a surface (2) wherein the method comprises the steps of: 
Postupak za oblikovanje površine otporne na habanje koja sadrži prozirne ili polu-prozirne čestice otporne na habanje (15) na površini (2), te je površina (2) praškasti sloj, naznačen time što postupak sadrži:
The Oxyntomodulin peptide analogue according to either Claim 1 or 2, wherein the analogue is PEGylated on the thiol of both Cys residues at positions 38 and 39 with an approximately 20 kDa PEG molecule in each case and comprises the amino acid sequence: wherein the carboxyl group of the PEGylated Cys at position 39 is optionally amidated. 
Peptidni analog oksintomodulina u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što je navedeni analog PEGiliran na tiolu u oba Cys ostatka na položajima 38 i 39 s približno 20 kDa molekulom PEG u oba slučaja i ima aminokiselinski slijed:
The formulation of claim 1, wherein said pH buffered saline solution has a pH of 5.5 to 7.5. 
Formulacija u skladu s patentnim zahtjevom 1, naznačena time što navedena fiziološka otopina s puferiranim pH ima pH od 5,5 do 7,5.
In embodiments where the third polymeric material is an at least partially neutralised polycarboxylic acid polymer, said method typically comprises dispersing a polycarboxylic acid polymer in a solvent, optionally with a buffer agent, and adding base to at least partially neutralise the polycarboxylic acid polymer to form the inner coating preparation. 
Postupak za koji se traži zaštita patentom u patentom zahtjevu 11 ili patentnom zahtjevu 12, spomenuti postupak sadrži disperziju polimera polikarboksilne kiseline u otapalu, izborno s puferskim sredstvom, i dodavanje baze da se barem delimično neutralizira polimer polikarboksilne kiseline da bi se formirao preparat unutarnje obloge.
said acid catalyst is preferably selected from the group consisting of mineral and organic acids. 
Postupak u skladu s patentnim zahtjevom 26, naznačen time što navedeni kiselinski katalizator se bira iz skupine koju čine mineralne i organske kiseline.
The method of claim 20, wherein said additional anti-hepatitis C virus agent is selected from the group consisting of a-interferon, B-interferon, ribavarin, and adamantine. 
Pripravak u skladu s patentnim zahtjevom 20, naznačen time, da rečeno dodatno sredstvo protiv virusa hepatitisa C je odabrano iz skupine koja se sastoji od a-interferona, B-interferona, ribavarina i adamantina.
Fresh cortex from male Wistar rats (125-225 g) are homogenized in 0.4M sucrose with a glass/teflon homogenizer. 
Svježi korteks muškog štakora (125-225 g) homogenizira se u 0.4M sukroze s staklo/teflon homogenizatorom.
The extended release dosage form of claim 78, wherein the extended release formulation and the immediate release formulation contain the same or different active agents. 
Oblik za doziranje s produljenim otpuštanjem prema zahtjevu 26, naznačen time da formulacija s produljenim otpuštanjem i formulacija za trenutno otpuštanje sadrže iste ili različite aktivne agense.
a first ratchet tooth of the first gear wheel is engaged and rotatably driven by the first ratchet drive pawl until the second ratchet drive pawl has travelled over the tip of a second ratchet tooth of the gear wheel with which it is arranged for engagement; and then the second ratchet tooth of the gear wheel is engaged and rotatably driven by the second ratchet drive pawl. 
prvi zaporni zub prvog kotača sa zupčanikom (30) je pokrenut i rotacijski pogonjen prvim pogonom zapornog zaklopca (28) dok je drugi pogon zapornog zaklopca (132) putovao preko vrha drugog zapornog zupca kotača sa zupčanikom s kojim je postavljen za pokretanje; i zatim drugi zaporni zubac kotača sa zupčanikom je pokrenut i rotacijski pogonjen drugim pogonom zapornog zaklopca (132).
X is N, CH and where X bears a double bond it is C; 
X je N, CH, a kada X nosi dvostruku vezu, navedeni je C;
at least one spring member (5a) acting between the gripping shanks, against the action of which the gripping shanks (10, 20) are pivotable from the closed position towards the open position, characterized in: 
- < najmanje jedne opruge (5a) koja djeluje između steznih držača, protivno djelovanju kojim se stezni držači (10, 20) zakreću iz zatvorenog položaja prema otvorenom položaju, naznačen time da:
Process according to claim 6, wherein the solvent is selected from isopropyl acetate, ethyl acetate and acetonitrile, more preferably from isopropyl acetate and ethyl acetate. 
Postupak prema zahtjevu 14 ili 15, naznačen time, da barem jedno otapalo je odabrano od alkohola, ketona, estera i etera, i poželjno je odabrano od izopropil acetata i tert-butil metiletera.
An apparatus according to claim 5, wherein the means for cooling comprises: 
Aparat prema patentnom zahtjevu 2, gdje sredstvo za hlađenje sadrži:
a bispecific antibody, wherein the first polypeptide is an H chain consisting of an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 2, the second polypeptide is an H chain consisting of an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 6, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 8; 
bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 2, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 6, a treći polipeptid i četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 8;
The flexible cover according to claim 1, wherein the peripheral edge of the flexible film is longer than the circumference of the loop when the elastic thread is in a relaxed state. 
Fleksibilni pokrov (1) sukladno bilo kojem od prethodnih Zahtjeva, pri čemu je periferni rub (8) fleksibilne folije (2) dulji od obujma petlje kada je elastična nit (3) u opuštenom stanju.
The antibody or antigen-binding fragment thereof for use of claim 24 or 25, wherein the antibody or antigen-binding fragment is co-administered with local radiation. 
Antitijelo ili njegov fragment vezan za antigen za uporabu prema zahtjevu 16 ili 17, naznačeno time što se antitijelo ili fragment vezan za antigen primjenjuje istodobno s lokalnim zračenjem.
The mouse of clause 24, wherein the mouse further comprises at an endogenous B2 microglobulin locus a nucleotide sequence encoding a human or humanized B2 microglobulin polypeptide. 
Miš prema zahtjevu 8 ili 12, naznačen time, da miš nadalje na endogenom fB2-mikroglobulin-lokusu, obuhvaća nukleotidnu sekvencu koja kodira humani ili humanizirani B2-mikroglobulin-polipeptid.
The method of aspect 64, wherein the viral infection is mediated by human immunodeficiency virus (HIV), hepatitis C virus (HCV), herpes simplex virus type I (HSV-1) or the Severe Acute Respiratory Syndrome (SARS) virus. 
Antitijelo ili antigen-vežući dio prema patentnom zahtjevu 13 za uporabu u postupku za tretman prema patentnom zahtjevu 13, gdje je virusna infekcija posredovana preko virusa humane imunodeficijencije (HIV), virusa hepatitisa
The orally dispersing tablet of claim 6, wherein the at least one disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, crosslinked carboxymethyl cellulose, low-substituted hydroxylpropylcellulose, mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, and combinations thereof. 
ODT sukladno patentnom zahtjevu 1, naznačena time, što je najmanje jedan dezintegrator odabran iz skupine koju čine krospovidon, natrijev škrob glikolat, umrežena karboksimetil celuloza, nisko supstituirana hidroksipropilceluloza, manitol, ksilitol, sorbitol, maltol, maltitol, laktoza, saharoza, maltoza i njihove kombinacije.
Use of the carbostyril derivative or a salt thereof as set forth in claim 1 or 2 for preparing a medicament for improving the descended action of donepezil or a salt thereof in the treatment of Alzheimer's disease. 
Uporaba derivata karbostirila ili njegove soli kako je navedeno u zahtjevu 1 ili 2, te donepezila ili njegove soli naznačena time da je za pripravu lijeka za liječenje Alzheimerove bolesti.
As a result, 48 g (82% yield) of [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid was obtained. 
Kao rezultat dobije se 48 g (82% prinos) [1-hidroksi-2-(3-piridiniljetiliden/bisfosfonske kiseline.
The pharmaceutical composition of claim 8, wherein the composition is non-enteric-coated, or wherein the composition is a tablet or a capsule; or wherein the composition further comprises an excipient selected from mannitol, microcrystalline cellulose, crospovidone, and magnesium stearate, or wherein the composition further comprises a permeation enhancer. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 8, gdje sastav dalje sadrži pomoćnu tvar izabranu između manitola, mikrokristalne celuloze, krospovidona i magnezijeva stearata. Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 9, gdje sastav dalje obuhvaća pojačivač permeacije.
Recombinant nucleic acid molecule according to any of claims 3 to 9, having the nucleic acid sequence as depicted in SEQ ID No. 
Rekombinantna molekula nukleinske kiseline prema bilo kojem od zahtjeva 2 do 8, ima sekvencu nukleinskih kiselina kako je prikazano za SEQ ID No.
The compound of claim 1 or 5 and/or a pharmaceutically acceptable salt thereof, wherein one of R3 and R4 is in which n is 1 and each of Ra, Rb, and Rc, independently, is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. 
Spoj patentnog zahtjeva 1 ili 5 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je jedno od R3 i R4 [image] gdje n je 1 i svaki od Ra, Rb, i Rc, nezavisno, je H, alkil, alkenil, alkinil, cikloalkil, heterocikloalkil, aril, ili heteroaril.
In one aspect of the present invention, the DPP-IV inhibitor is orally active. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da DPP-IV inhibitor je oralno aktivan.
The pharmaceutical formulation of claim 19, wherein said formulation is an oral formulation. 
Farmaceutska formulacija u skladu s patentnim zahtjevom 19, pri čemu je navedena formulacija formulacija za oralnu primjenu.
The method can include contacting an aqueous suspension of hydrated cloquintocet-mexyl with a surfactant selected from the group consisting of a tallowamine alkoxylate, a cocoamine alkoxylate, and mixtures thereof to form a stabilized composition, wherein the stabilized composition is stable at a temperature of 30° C. or greater. 
HR P20182057 T1 PATENTNI ZAHTJEVI Postupak smanjivanja rasta kristala iz vodene suspenzije hidratiranog klokintocet-meksila, naznačen time što se sastoji u: stavljanju u kontakt vodene suspenzije hidratiranog klokintocet-meksila sa surfaktantom kojeg se bira iz skupine koju čine loj-amin-alkoksilat, kokos-amin-alkoksilat, te njihove smjese, kako bi se dobilo stabilizirani pripravak.
A kit comprising a container as claimed in claim 14, 15 or 16, or a kit as claimed in claim 17, together with a measuring accessory for measuring out a defined volume of the solution. 
Komplet, naznačen time što sadrži spremnik u skladu s patentnim zahtjevom 14, 15 ili 16, ili komplet u skladu s patentnim zahtjevom 17, kao i mjerni pribor za mjerenje definiranog volumena otopine.
The process according to claim 5, wherein a compound is added the first aliquot of the at least two aliquots, a second aliquot of the at least two aliquots remains without addition of the compound, and that following the application of shear-force, a change of the aggregated conformation prion protein in the first aliquot is detected in relation to the aggregated conformation prion protein in the second aliquot. 
Postupak prema zahtjevu 8, naznačeno time da je spoj dodan prvom alikvotu tekućeg sastava, drugi alikvot ostaje bez dodanog spoja, te se daljnjom primjenom sile smicanja zamijećuje promjena u prvom alikvotu u odnosu na prionski protein agregirane konformacije u drugom alikvotu.
The tablet of claim 1, wherein the tableting aid further comprises a disintegrant. 
Tableta prema zahtjevu 1, naznačena time, da pomoćno sredstvo za tabletiranje nadalje obuhvaća dezintegrator.
The dosage form for use of claim 3 or 4, wherein said amount of crystalline trans-(±)-A9-tetrahydrocannabinol is within a range of from 0.1 mg to 100 mg, preferably within a range of from 0.5 mg to 75 mg, more preferably from 2 mg to 50 mg, and most preferably from 5 mg to 25 mg. 
Oblik doziranja za upotrebu prema zahtjevima 3 ili 4, naznačen time da je navedena količina kristalnog trans-(±)-A9-tetrahidrokanabinola unutar raspona of 0.1 mg do 100 mg, poželjno unutar raspona od 0.5 mg do 75 mg, poželjnije od 2 mg do 50 mg, i najpoželjnije od 5 mg do 25 mg.
Further provided is a package comprising (b) an M3 antagonist of the invention and (a) a B2 agonist for the simultaneous, concurrent, separate or sequential use in the treatment of a said respiratory disease, while producing less heart side-effects than a therapeutically equivalent combination of tiotropium with the B2 agonist. 
Također je omogućena proizvodnja paketa koji sadrži (b) M3 antagonist sukladno predmetnom izumu i (a) kortikosteroid za istovremenu, paralelnu, odvojenu ili seckvencijalnu uporabu u liječenju navedenih respiratornih bolcsti.
In prospective, controlled studies, women with recurrent vulvovaginal candidiasis had a beneficial effect while on prophylaxis with long-term oral imidazole derivatives, but that relapse was common after withdrawal of the drug. 
U perspektivnim, kontroliranim istraživanjima, bilo je koristi u žena dok su bile na profilaktičkom dugoročnom oralnom tretmanu s derivatima imidazola, ali povratak bolesti bio je uobičajen nakon bio je uobičajen nakon prestanka uzimanja lijeka.
Compound according to the preceding claim, selected from the group comprising of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj Formule V: ne nF
The variant of claim 7, comprising the substitution P10Q. 
Varijanta iz zahtjeva 7, naznačena time, da sadrži supstituciju P10Q.
In an embodiment of the method according to the invention, after the pressure stage, the content of wood preservative on the surface layer of wood is adjusted to less than 75% of the dry weight of wood. 
Postupak sukladno Zahtjevu 1 ili 2, naznačen time što je, nakon faze pritiska, sadržaj konzervansa za drvo na površinskom sloju drveta prilagođen na manje od 75% suhe težine drveta.
In some embodiments, the blood-brain barrier agent is not L-R-K-L-R-K-R-L-L-R-L-R-K-L-R-K-R-L-L-R (SEQ ID NO:141). A hydrophilic amino acid (X) can be chosen from arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, tyrosine, or a combination thereof. 
Peptid nosač prema zahtjevu 1, naznačen time da svaki X je neovisno odabran od arginina, asparagina, asparaginske kiseline, glutaminske kiseline, glutamina, histidina, lizina, serina, treonina, i tirozina, ili pri čemu n je odabran od 4, 8, 12, 16, i 20, ili pri čemu mje 1.
A benzazepine compound represented by general formula (1) wherein R1 is a group of (1-5): 
HR P20120310 T1 PATENTNI ZAHTJEVI m» Spoj benzazepina, naznačen time, da je predstavljen općom formulom (1) gdje:
The pharmaceutical composition of claim 1, further comprising an active ingredient selected from the group consisting of ACE inhibitors, angiotensin receptor antagonists, beta-2 receptor agonists, phosphodiesterase inhibitors, glucocorticoid receptor agonists, diuretics, or recombinant angiotensin converting enzyme-2 and acetylsalicylic acid (aspirin). 
Lijek prema bilo kojem od zahtjeva 1 do 4, naznačen time da je nadalje u kombinaciji s dodatnim aktivnim sastojkom odabranim iz skupine koja se sastoji od ACE inhibitora, antagonista angiotenzinskih receptora, agonista beta-2 receptora, inhibitora fosfodiesteraze, agonista glukokortikoidnog receptora, diuretika, rekombinantnog angiotenzin pretvarajućeg enzima-2 i acetilsalicilne kiseline.